Research ArticleCancer

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

+ See all authors and affiliations

Science Translational Medicine  14 Jun 2017:
Vol. 9, Issue 394, eaal5253
DOI: 10.1126/scitranslmed.aal5253

Log in to view full text


Navigate This Article